Composition with whitening effect and application thereof

Abstract

The invention relates to a composition with a whitening effect and application thereof, and belongs to the technical field of cosmetics. The composition with the whitening effect is prepared from the following components in parts by mass: 1 to 3 parts of phenylethyl resorcinol, 0.1 to 0.5 part of hexapeptide-2, 0.1 to 0.3 part of compound PDRN and 2 to 4 parts of nicotinamide, wherein the compound PDRN is prepared from negundo chastetree leaf PDRN, glycyrrhiza glabra PDRN and desert rose PDRN in a mass ratio of 1 to (1 to 3) to (2 to 4). The composition with the whitening effect has a remarkable effect of inhibiting tyrosinase, and is mild, non-irritant and wide in applicability.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a composition with whitening effect and its application. Background Technology

[0002] With the development of society and the economy and the improvement of people's aesthetic standards, skin whitening has become one of the important demands in the cosmetics industry. Existing whitening products on the market typically rely on multiple active ingredients, such as arbutin, vitamin C derivatives, and kojic acid. These ingredients achieve whitening effects by inhibiting tyrosinase activity or interfering with melanin synthesis pathways. However, these traditional ingredients have many limitations in practical applications: First, many ingredients are highly irritating, easily causing skin allergies, redness, or dryness, especially unfriendly to people with sensitive skin; second, the whitening effect of a single ingredient is often limited, requiring high concentrations to achieve the desired effect, which may exacerbate the burden on the skin; in addition, some ingredients have poor stability and are easily degraded by factors such as light and heat, affecting the product's shelf life and efficacy.

[0003] To enhance whitening effects and reduce irritation, existing technologies often employ compound formulations, combining multiple whitening ingredients. However, poor compatibility or insufficient synergy between ingredients can lead to insignificant results or adverse reactions. For example, improper ingredient ratios in some compound formulations may fail to effectively inhibit tyrosinase and could even trigger inflammatory responses. Therefore, developing a gentle yet highly effective whitening composition with synergistic effects between its ingredients has become an urgent need in the field of cosmetic technology.

[0004] Based on the shortcomings of the prior art, this invention aims to provide a novel whitening composition that achieves a significant tyrosinase inhibition effect through the optimized ratio of specific ingredients (such as phenylethyl resorcinol, hexapeptide-2, compound PDRN and niacinamide), while ensuring the product's gentleness and wide applicability. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a composition with whitening effect and its application.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a composition having whitening effects, the composition comprising the following components in parts by weight: Phenethyl resorcinol: 1-3 parts; Hexapeptide-2: 0.1-0.5 parts; Nicotinamide: 2-4 parts; Compound PDRN: 0.1-0.3 parts; The compound PDRN includes at least one of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN.

[0007] Preferably, the whitening composition comprises the following components in parts by weight: Phenethyl resorcinol: 2 parts; Hexapeptide-2: 0.3 parts; Nicotinamide: 3 parts; Compound PDRN: 0.2 parts; The compound PDRN includes at least one of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN.

[0008] Preferably, the composite PDRN comprises Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:1-3:2-4.

[0009] Within the preferred formulation range, the whitening composition of the present invention exhibits better inhibition of tyrosinase.

[0010] Secondly, the present invention provides the use of the whitening composition described in the first aspect in the preparation of cosmetics with whitening effects.

[0011] Preferably, the cosmetic dosage form includes any one of serum, lotion, cream, spray, and mask.

[0012] Thirdly, the present invention provides a whitening serum, the serum comprising the following components by weight percentage: The whitening composition described in the first aspect: 0.5-2 wt%; Decarboxylcarnosine hydrochloride: 0.5-0.8 wt%; Mannitol: 0.1-2.5 wt% Hydroxypropyl cyclodextrin: 0.1-9 wt% 1,2-Hexanediol: 0.1-20 wt% Add deionized water to bring the total to 100 wt%.

[0013] Preferably, the preparation method of the whitening serum includes the following steps: S1: Mix 1,2-hexanediol, 1 / 2 deionized water and the composition with whitening effect evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 60-70℃, add hydroxypropyl cyclodextrin, stir well to obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 30-45℃, stir well, and obtain the essence.

[0014] Compared with the prior art, the beneficial effects of the present invention are as follows: The whitening composition of this invention is not a simple superposition of the functions of its components, but rather achieves effective inhibition of melanin production through synergistic effects across multiple targets and pathways. Its possible mechanism of action is as follows: 1. Directly inhibit tyrosinase activity (targeted blockade) Phenethyl resorcinol: It can competitively bind to the active site of tyrosinase, directly inhibiting the catalytic function of the enzyme, thereby reducing the production of dopaquinone, a precursor to melanin synthesis. This is a key step in blocking melanin production at its source.

[0015] Compound PDRN: The nucleotides and nucleosides it provides may participate in regulating the metabolic environment of skin cells, and have a certain downregulating effect on the expression or conformation of tyrosinase, indirectly weakening its activity.

[0016] 2. Intervention in the melanin synthesis signaling pathway (upstream regulation) Hexapeptide-2: As a bioactive peptide, its core mechanism may lie in interfering with the binding of melanocyte-stimulating signals such as α-melanocyte-stimulating hormone to melanocyte membrane receptors. By blocking this key signal transduction pathway, the production of intracellular cAMP can be reduced upstream, thereby downregulating the expression of tyrosinase and related proteins, achieving "signal cascade inhibition".

[0017] 3. Inhibits the transfer and transport of melanin to keratinocytes. Niacinamide: Its main target is the downstream process of melanin production. Niacinamide can effectively inhibit the transport of melanosomes from melanocytes to surrounding keratinocytes. This means that even if a small amount of melanin is produced, its transport to the skin surface will be blocked, thus preventing the melanin already produced from appearing in the epidermis and achieving a brighter skin tone.

[0018] 4. Repair and nourish, creating a microenvironment unfavorable to excessive melanin production. Compound PDRN (derived from Vitex negundo leaf, Glycyrrhiza glabra, and Rosa desertica): The combined action of these three plant-derived PDRNs provides skin cells with abundant nucleotide raw materials, helping to promote cellular DNA repair and regeneration, and enhancing overall cell vitality. A healthy and stable skin microenvironment helps maintain normal metabolic balance, indirectly reducing pigmentation caused by inflammation, damage, or stress.

[0019] In summary, the composition of the present invention, through a whole-chain, multi-target intervention mode of "signal pathway → enzyme activity inhibition → product transport", enables the components to work together to produce a synergistic effect of "1+1+1+1 > 4", thereby achieving a significant whitening effect at a low concentration. Furthermore, because its mechanism of action is more gentle and natural, it avoids the irritation risks that may be caused by the use of high concentrations of a single ingredient. Detailed Implementation

[0020] To better understand the present invention, the present invention will be further described below with reference to specific embodiments. The terms used in "composition" and "application example" are for describing specific implementation schemes and do not constitute a limitation on the scope of protection of the present invention.

[0021] Unless otherwise specified, experimental methods in the following examples are generally performed under standard conditions or as recommended by the manufacturer. Unless otherwise stated, all measurements are by percentage and parts by mass.

[0022] Some of the raw materials and their sources are as follows: Phenethyl resorcinol: Purchased from Guangzhou Aoxue Chemical Co., Ltd., batch number 2025A15025.

[0023] Hexapeptide-2: Purchased from Guangzhou Best Chemical Co., Ltd., batch number 20250416.

[0024] Nicotinamide: Purchased from Guangzhou Baihaobo Co., Ltd., batch number VBLO62NSEG27.

[0025] Vitex negundo PDRN: Guangzhou Xinyingke Chemical Co., Ltd., batch number ASB2025100701.

[0026] Licorice glazei PDRN: Guangzhou Xinyingke Chemical Co., Ltd., batch number ASB2024050402.

[0027] Desert Rose PDRN: Guangzhou Xinyingke Chemical Co., Ltd., batch number ASB2025050111.

[0028] PDRN-1: Purchased from Regimin Biotechnology, raw material: male salmon testes.

[0029] Unless otherwise specified, all other materials and reagents used in the specific implementation methods are commercially available.

[0030] Preparation of a composition with whitening effect Composition 1 Composed of the following components by mass: Phenethyl resorcinol: 2 parts; Hexapeptide-2: 0.3 parts; Nicotinamide: 3 parts; Compound PDRN: 0.2 parts; The compound PDRN is composed of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:2:3; Preparation method: Mix the above components evenly according to the mass parts, seal and store in the dark.

[0031] Composition 2 Composed of the following components by mass: Phenethyl resorcinol: 1 part; Hexapeptide-2: 0.1 parts; Nicotinamide: 2 parts; Compound PDRN: 0.1 part; The compound PDRN is composed of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:1:2; The preparation method is the same as that of composition 1.

[0032] Composition 3 Composed of the following components by mass: Phenethyl resorcinol: 3 parts; Hexapeptide-2: 0.5 parts; Nicotinamide: 4 parts; Compound PDRN: 0.3 parts; The compound PDRN is composed of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:3:4. The preparation method is the same as that of composition 1.

[0033] Composition ① Unlike composition 1, it lacks phenylethyl resorcinol; the missing mass fraction is made up by hexapeptide-2 and nicotinamide in a mass ratio of 0.3:3, and the remaining components, their mass fractions, and preparation methods are the same as those in composition 1.

[0034] Composition ② Unlike composition 1, it lacks hexapeptide-2; the missing mass fraction is made up by phenylethyl resorcinol and nicotinamide in a mass ratio of 2:3, and the remaining components, mass fractions, and preparation methods are the same as those in composition 1.

[0035] Composition ③ Unlike composition 1, this composition lacks nicotinamide; the missing mass fraction is made up by phenylethyl resorcinol and hexapeptide-2 in a mass ratio of 2:0.3, and the remaining components, their mass fractions, and preparation methods are the same as those in composition 1.

[0036] Composition A Unlike composition 1, the composite PDRN is composed of licorice PDRN and desert rose PDRN in a mass ratio of 2:3, while the other components, their mass fractions, and preparation methods are the same as those in composition 1.

[0037] Composition B Unlike composition 1, the composite PDRN is composed of Vitex negundo leaf PDRN and Rosa desertica PDRN in a mass ratio of 1:3. The other components, their mass fractions, and preparation methods are the same as those in composition 1.

[0038] Composition C Unlike composition 1, the composite PDRN is composed of Vitex negundo leaf PDRN and Glycyrrhiza glabra PDRN in a mass ratio of 1:2. The remaining components, their mass fractions, and preparation methods are the same as those in composition 1.

[0039] Composition D Unlike composition 1, the composite PDRN is composed of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:1:1. The other components, their mass fractions, and preparation methods are the same as those of composition 1.

[0040] Composition E Unlike composition 1, PDRN-1 is used in an equal mass fraction to replace the composite PDRN, while the remaining components, their mass fractions, and preparation methods are the same as in composition 1.

[0041] Composition α Unlike composition 1, it lacks phenylethyl resorcinol, hexapeptide-2, and nicotinamide. The missing mass fractions are made up by composite PDNR, in which the composition of composite PDNR is the same as that of composition 1, and the other components, their mass fractions, and preparation methods are the same as those of composition 1.

[0042] Composition β Unlike composition 1, this composition lacks composite PDRN. The missing mass fraction is made up by phenylethyl resorcinol, hexapeptide-2, and nicotinamide in a mass ratio of 2:0.3:3. The remaining components, their mass fractions, and preparation methods are the same as those in composition 1.

[0043] Composition λ Composed of the following components by mass: Phenethyl resorcinol: 0.2 parts; Hexapeptide-2: 2 parts; Nicotinamide: 0.3 parts; Compound PDRN: 3 parts; The composite PDRN is composed of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:4:1. The preparation method is the same as that of composition 1.

[0044] A whitening serum, its components and preparation method are as follows: Serum 1 Composed of the following components by mass percentage: Composition 1: 1.5 wt% Decarboxylated carnosine hydrochloride: 0.7 wt%; Mannitol: 1.2 wt% Hydroxypropyl cyclodextrin: 3wt% 1,2-Hexanediol: 14wt%; Deionized water to 100 wt%; The preparation method of serum 1 is as follows: S1: Mix 1,2-hexanediol, 1 / 2 deionized water and the composition evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 65°C, add hydroxypropyl cyclodextrin, stir well, and obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 37°C, stir well, and obtain the essence.

[0045] Serum 2 Composed of the following components by mass percentage: Composition 1: 0.5 wt% Decarboxylated carnosine hydrochloride: 0.5 wt% Mannitol: 0.1 wt% Hydroxypropyl cyclodextrin: 0.1 wt% 1,2-Hexanediol: 0.1 wt% Deionized water to 100 wt%; The preparation method of serum 2 is as follows: S1: Mix 1,2-hexanediol, 1 / 2 deionized water and the composition evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 70°C, add hydroxypropyl cyclodextrin, stir well to obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 45°C, stir well, and obtain the essence.

[0046] Serum 3 Composed of the following components by mass percentage: Composition 1: 2wt% Decarboxylated carnosine hydrochloride: 0.8 wt% Mannitol: 2.5 wt% Hydroxypropyl cyclodextrin: 9 wt% 1,2-Hexanediol: 20wt% Deionized water to 100 wt%; The preparation method of serum 3 is as follows: S1: Mix 1,2-hexanediol, 1 / 2 deionized water and the composition evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 60°C, add hydroxypropyl cyclodextrin, stir well, and obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 30°C, stir well, and obtain the essence.

[0047] Serum 4 Unlike serum 1, composition 2 is used to replace composition 1 by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0048] Serum 5 Unlike serum 1, composition 3 is used to replace composition 1 by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0049] Serum ① Unlike serum 1, composition 1 is replaced by composition ① at the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0050] Serum ② Unlike serum 1, composition 2 is used to replace composition 1 by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0051] Serum ③ Unlike serum 1, composition 3 is used to replace composition 1 by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0052] Serum A Unlike serum 1, composition A is used to replace composition 1 by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0053] Serum B Unlike serum 1, composition 1 is replaced by composition B at the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0054] Serum C Unlike serum 1, composition 1 is replaced by composition C at the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0055] Serum D Unlike serum 1, composition 1 is replaced by composition D at the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0056] Serum E Unlike serum 1, composition 1 is replaced by composition E by the same mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0057] serum α Unlike serum 1, composition α is used to replace composition 1 by a certain percentage by mass, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0058] serum beta Unlike serum 1, composition β is used to replace composition 1 by a mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0059] serum Unlike serum 1, composition λ is used to replace composition 1 by a mass percentage, while the remaining components, their mass percentages, and preparation methods are the same as those in serum 1.

[0060] Blank Essence Composed of the following components by mass percentage: Decarboxylated carnosine hydrochloride: 0.7 wt%; Mannitol: 1.2 wt% Hydroxypropyl cyclodextrin: 3wt% 1,2-Hexanediol: 14wt%; Deionized water to 100 wt%; The preparation method for blank serum is as follows: S1: Mix 1,2-hexanediol and 1 / 2 deionized water evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 65°C, add hydroxypropyl cyclodextrin, stir well, and obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 37°C, stir well, and obtain blank essence.

[0061] Test Example 1 1.1 Tyrosinase activity inhibition test Test substance: Prepare a 0.5 g / L solution of the composition (compositions 1-3, ①-③, AE, α, β, λ) using sterile deionized water for testing; prepare as needed.

[0062] Test medium: The test medium is prepared by mixing the test medium with the test substance, wherein the volume fraction of the test substance is 1%.

[0063] Logarithmic growth phase mouse melanoma B16 cells were seeded into 6-well cell culture plates and cultured overnight. The test culture medium was added, with an untreated group serving as the cell control group; two replicates were performed for each group. After 48 hours of culture, the cells were washed once with PBS, and 100 μL of lysis buffer was added to each well. Cells were scraped and collected, and the supernatant was collected by centrifugation. 50 μL of the cell supernatant was transferred to a 96-well plate, and 50 μL of 1 wt% L-DOPA solution was added. The plate was incubated at 37°C for 1 hour, and the absorbance was read at 475 nm using an M3 plate reader.

[0064] Relative tyrosinase activity (%) = absorbance value of test group / absorbance value of cell control group × 100%.

[0065] 1.2 Melanin Synthesis Inhibition Test Test substance: Prepare a 0.5 g / L solution of the composition (compositions 1-3, ①-③, AE, α, β, λ) using sterile deionized water for testing; prepare as needed.

[0066] Test medium: The test medium is prepared by mixing the test medium with the test substance, wherein the volume fraction of the test substance is 1%.

[0067] Logarithmic growth phase mouse melanoma B16 cells were seeded in T25 cell culture flasks and cultured overnight. Test culture media were added separately, with the untreated group serving as the cell control. After 48 hours of culture, the cells were washed once with PBS, and 1 mL of 1 mol / L NaOH solution was added. The cells were scraped and collected, placed in an 80°C water bath for 30 minutes, and the supernatant was added to a 96-well plate. The absorbance was read at 475 nm using an M3 plate reader.

[0068] Relative melanin content (%) = absorbance value of test group / absorbance value of cell control group × 100%.

[0069] The results of the tyrosinase activity and melanin synthesis inhibition experiments are shown in Table 1. The tyrosinase activity of the cell control group was 100%, and the melanin content of the cell control group was 100%.

[0070] Table 1. Effects of the composition on tyrosinase activity and melanin content. test substance Relative tyrosinase activity (%) Relative melanin content (%) Composition 1 26.4 47.2 Composition 2 27.6 49.1 Composition 3 26.9 47.9 Composition ① 38.5 58.8 Composition ② 36.3 57.5 Composition ③ 39.4 59.6 Composition A 32.7 54.1 Composition B 34.6 56.9 Composition C 33.4 55.2 Composition D 32.1 53.9 Composition E 37.5 58.2 Composition α 43.1 63.3 Composition β 33.2 54.8 Composition λ 30.4 53.4 As shown in Table 1, the composition has a certain effect in inhibiting tyrosinase activity and reducing melanin content. Comparing the results of compositions 1-3 and composition λ, it can be seen that the composition exhibits the best effect in inhibiting tyrosinase activity and reducing melanin content within the mass ratio range specified in this invention. Comparing the results of composition 1 with compositions ①-③, it can be seen that phenylethyl resorcinol, hexapeptide-2, and nicotinamide in this invention have a synergistic effect, and their combined use can significantly reduce tyrosinase activity and melanin content. Comparing the results of composition 1 with composition AE, it can be seen that the PDRN from Vitex negundo leaf in the composite PDRN of this invention... The PDRN from Glycyrrhiza glabra and Rosa desertica exhibits a significant synergistic effect. Within the range of raw materials and their mass ratios defined in this invention, the composite PDRN can significantly enhance the inhibitory effect of the composition on tyrosinase activity and reduce melanin content. Comparing the results of composition 1 with composition α and composition β, it can be seen that although phenylethyl resorcinol, hexapeptide-2, and nicotinamide in this invention have certain effects in inhibiting tyrosinase activity and reducing melanin content, the composition obtained by mixing them with the composite PDRN in the mass ratios defined in this invention has better effects in inhibiting tyrosinase activity and reducing melanin content.

[0071] Test Example 2 Security test The irritation of cosmetics was evaluated using the 2015 Cosmetic Safety Technical Specifications as a reference standard. The test method was a skin patch test, and the test was conducted on volunteers aged 16-65 years who were randomly distributed. Each volunteer was assigned to all test products, for a total of 30 volunteers.

[0072] Test substances: serums 1-5, serums ①-③, serum AE, serum α, serum β, serum λ, and blank serum.

[0073] Test Method: The volunteer's back was divided into 17 test areas using tape. The test substance was placed in a patch applicator at a dosage of 0.020-0.025g. The patch applicator containing the test substance was then covered with non-irritating cloth-based adhesive tape over the test area. One sample was used for each test area. The patch was gently pressed with the palm of the hand to ensure even adhesion to the skin surface. The application was left on for 24 hours. The patch applicator was removed 30 minutes later, and the skin reaction was observed after the pressure marks disappeared. If the result was negative, the results were repeated at 24 and 48 hours after the patch test.

[0074] Evaluation criteria: Grade 0: Negative reaction; Grade 1: Suspicious reaction, with only slight erythema; Grade 2: Weak positive reaction, erythema, infiltration, edema, and possible papules; Grade 3: Strong positive reaction, erythema, infiltration, edema, papules may be present, and the reaction may extend beyond the test area; Grade 4: Extremely positive reaction, with obvious erythema, severe infiltration, edema, confluent herpes, and reaction extending beyond the test area.

[0075] Test results: All subjects had negative skin reactions.

[0076] Test Example 3 Human efficacy test Test substances: serums 1-5, serums ①-③, serum AE, serum α, serum β, serum λ, and blank serum.

[0077] Female volunteers aged 25-50 were selected and randomly divided into groups of 10. Each group was assigned a test substance, which was applied to the face twice a day, morning and evening, for a total of 4 weeks.

[0078] Evaluation Method: The changes in skin melanin content in volunteers before and after using the test substance were assessed using a Hexameter MX18 skin red-melanin analyzer, and the rate of reduction in melanin content was calculated. The measurement range of the instrument is 0-999; the higher the measured value, the higher the melanin content in the skin.

[0079] Melanin content reduction rate / % = (pre-use test value - post-use test value) / test value after use × 100%.

[0080] The reduction rate of melanin in the facial skin of volunteers before and after using the essence prepared by this invention is shown in Table 2.

[0081] Table 2. Effects of serum on melanin content in human face test substance Melanin content reduction rate / % Serum 1 30.2 Serum 2 24.6 Serum 3 31.3 Serum 4 28.7 Serum 5 29.4 Serum ① 15.2 Serum ② 16.4 Serum ③ 14.4 Serum A 19.7 Serum B 17.1 Serum C 18.2 Serum D 20.3 Serum E 15.7 serum α 13.1 serum beta 18.9 serum 21.6 Blank Essence 1.7 As shown in Table 2, the serum has a certain effect in reducing melanin content. Comparing the serum with the blank serum, the blank serum itself does not have the effect of reducing epidermal melanin content; the efficacy of the serum depends on the composition within it. Comparing the results of serums 1-3, the mass percentage of the composition in the serum has a significant impact on its efficacy. Comparing the results of serum 1 with serums 4-5, ①-③, AE, α, β, and λ, the serum containing the composition within the raw materials and mass range specified in this invention exhibits the best melanin content reduction rate, indicating a significant synergistic effect among the raw materials in this invention, consistent with the aforementioned experimental results.

[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A composition having whitening effects, characterized in that, The composition comprises the following components in parts by weight: Phenethyl resorcinol: 1-3 parts; Hexapeptide-2: 0.1-0.5 parts; Nicotinamide: 2-4 parts; Compound PDRN: 0.1-0.3 parts; The compound PDRN includes at least one of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN.

2. The composition according to claim 1, characterized in that, The composition comprises the following components in parts by weight: Phenethyl resorcinol: 2 parts; Hexapeptide-2: 0.3 parts; Nicotinamide: 3 parts; Compound PDRN: 0.2 parts; The compound PDRN includes at least one of Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN.

3. The composition according to claim 1 or 2, characterized in that, The composite PDRN includes Vitex negundo leaf PDRN, Glycyrrhiza glabra PDRN, and Rosa desertica PDRN in a mass ratio of 1:1-3:2-4.

4. The use of the composition according to any one of claims 1-3 in the preparation of a cosmetic with whitening effects.

5. The application as described in claim 4, characterized in that, The cosmetic dosage forms include any one of serum, lotion, cream, spray, and mask.

6. A whitening serum, characterized in that, The serum comprises the whitening composition according to any one of claims 1-3.

7. The essence as described in claim 6, characterized in that, The serum also includes cosmetically acceptable excipients.

8. A whitening serum, characterized in that, The serum comprises the following components by weight percentage: The whitening composition according to any one of claims 1-3: 0.5-2 wt%; Decarboxylcarnosine hydrochloride: 0.5-0.8 wt%; Mannitol: 0.1-2.5 wt%; Hydroxypropyl cyclodextrin: 0.1-9 wt%; 1,2-Hexanediol: 0.1-20 wt%; Add deionized water to bring the total to 100 wt%.

9. The essence as described in claim 1, characterized in that, The preparation method of the serum includes the following steps: S1: Mix 1,2-hexanediol, 1 / 2 deionized water and the composition with whitening effect evenly to obtain mixture A; S2: Mix decarboxylated carnosine hydrochloride, mannitol and 1 / 4 deionized water to obtain mixture B; S3: Heat the remaining deionized water to 60-70℃, add hydroxypropyl cyclodextrin, stir well to obtain mixture C; S4: Mix mixture A, mixture B, and mixture C cooled to 30-45℃, stir well, and obtain the essence.